DMB-I (Latrepirdine/Dimebolin) Phase 3 (NCT07251023) — Alzheimer's Disease
Executive Summary
flowchart TD
clinical_trials_nct07251023["DMB-I Latrepirdine Phase 3 NCT07251023 Alz"]
style clinical_trials_nct07251023 fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_nct0_0["Executive Summary"]
clinical_trials_nct07251023 -->|"includes"| clinical_trials_nct0_0
style clinical_trials_nct0_0 fill:#81c784,stroke:#333,color:#000
clinical_trials_nct0_1["Trial Overview"]
clinical_trials_nct07251023 -->|"includes"| clinical_trials_nct0_1
style clinical_trials_nct0_1 fill:#ef5350,stroke:#333,color:#000
clinical_trials_nct0_2["Background: Latrepirdine/Dimebolin"]
clinical_trials_nct07251023 -->|"includes"| clinical_trials_nct0_2
style clinical_trials_nct0_2 fill:#ffd54f,stroke:#333,color:#000
clinical_trials_nct0_3["Historical Context"]
clinical_trials_nct07251023 -->|"includes"| clinical_trials_nct0_3
style clinical_trials_nct0_3 fill:#ce93d8,stroke:#333,color:#000
clinical_trials_nct0_4["Previous Clinical Studies"]
clinical_trials_nct07251023 -->|"includes"| clinical_trials_nct0_4
style clinical_trials_nct0_4 fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_nct0_5["Mechanism of Action"]
clinical_trials_nct07251023 -->|"includes"| clinical_trials_nct0_5
style clinical_trials_nct0_5 fill:#81c784,stroke:#333,color:#000
...DMB-I (Latrepirdine/Dimebolin) Phase 3 (NCT07251023) — Alzheimer's Disease
Executive Summary
Mermaid diagram (expand to render)
This Phase 3 clinical trial evaluates DMB-I (also known as dimebolin or latrepirdine), a small molecule compound with multi-target neuroprotective properties for the treatment of dementia associated with Alzheimer's disease. Originally developed in Russia, latrepirdine has a complex history in Alzheimer's drug development, with this trial representing an attempt to establish its efficacy through modern clinical trial methodology.
The trial is sponsored by Bigespas LTD and is being conducted at multiple centers in Russia. Unlike antibody-based therapies that target amyloid directly, latrepirdine works through multiple mechanisms including mitochondrial protection, anti-inflammatory effects, and potential amyloid modulation.
Trial Overview
| Parameter | Value |
|-----------|-------|
| NCT Number | NCT07251023 |
| Drug Name | DMB-I (dimebolin, latrepirdine) |
| Phase | Phase 3 |
| Status | Recruiting |
| Sponsor | Bigespas LTD |
| Enrollment | 450 participants |
| Enrollment Type | Estimated |
| Study Type | Interventional |
| Start Date | November 20, 2025 |
| Completion Date | May 1, 2027 |
| Duration | 26 weeks (6 months) |
Background: Latrepirdine/Dimebolin
Historical Context
Latrepirdine (also known as dimebolin and previously as Dimebolin) is an interesting compound with a unique developmental history:
Soviet development: Originally developed in Russia as an antihistamine in the 1980s
Serendipitous discovery: Found to have neuroprotective properties during routine testing
Alzheimer's research: Investigated for AD since the 1990s in Russia
Western attention: Gained interest from major pharmaceutical companies in the 2000sPrevious Clinical Studies
Latrepirdine has been studied in multiple clinical trials:
| Trial | Phase | Population | Result |
|-------|-------|------------|--------|
| Russian trials (1990s-2000s) | Various | AD, vascular dementia | Positive cognitive effects |
| Phase 2 (2009) | Phase 2 | Mild-to-moderate AD | Improved cognition vs. placebo |
| HORIZON (2013) | Phase 3 | Huntington's disease | Failed to meet primary endpoint |
| Extension studies | Open-label | AD | Maintained benefit over 12 months |
The failure in Huntington's disease (HORIZON trial) raised questions about efficacy but may reflect disease-specific effects or trial design issues.
Mechanism of Action
Latrepirdine is a multi-target drug with several proposed mechanisms:
1. Mitochondrial Protection
- Complex I stabilization: Preserves mitochondrial electron transport chain function
- ATP preservation: Maintains cellular energy levels
- ROS reduction: Decreases reactive oxygen species production
- Apoptosis inhibition: Prevents mitochondrial-triggered cell death
2. Amyloid Interaction
- Amyloid aggregation inhibition: Prevents Aβ oligomer formation
- Amyloid fibril disruption: May disaggregate existing plaques
- Neural protection: Blocks Aβ-induced toxicity
3. Anti-inflammatory Effects
- Microglial modulation: Reduces chronic neuroinflammation
- Cytokine suppression: Decreases IL-1β, TNF-α
- Neuroprotection: Reduces excitotoxicity
4. Additional Effects
- Calcium homeostasis: Modulates intracellular calcium
- Neurotransmitter modulation: May affect glutamate, GABA
- Neurotrophic support: May enhance survival pathways
This multi-target profile distinguishes latrepirdine from more selective AD drugs.
Study Design
Trial Type
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, active comparator-controlled study.
Design Rationale
The inclusion of an active comparator arm reflects:
- Historical context: Latrepirdine has been approved in Russia
- Regulatory requirements: May require demonstration vs. standard of care
- Clinical relevance: Provides context for interpreting results
Randomization
- Ratio: Not specified but likely 1:1 or 1:1:1 (placebo: active)
- Stratification: By disease severity
- Allocation: Computer-generated random assignment
Treatment Arms
| Arm | Treatment | Description |
|-----|-----------|-------------|
| Active 1 | DMB-I (high dose) | Higher dose of latrepirdine |
| Active 2 | DMB-I (low dose) | Lower dose of latrepirdine |
| Placebo | Matching placebo | Inactive control |
Duration
- Treatment period: 26 weeks (6 months)
- Assessments: Baseline, 4 weeks, 12 weeks, 26 weeks
- Follow-up: Post-treatment safety follow-up
Primary Endpoint
ADAS-Cog Score Change at Week 26
The primary endpoint is the change in ADAS-Cog (Alzheimer's Disease Assessment Scale - Cognitive subscale) overall score at Week 26 compared to baseline.
What is ADAS-Cog?
The ADAS-Cog is the gold-standard cognitive assessment for AD clinical trials:
Components:
- Word recall tasks (memory)
- Naming objects
- Commands
- Constructional praxis
- Ideational praxis
- Orientation
- Word recognition
- Memory
Scoring:
- 0-70 points (higher = worse)
- Minimum clinically important difference: 3-4 points
Rationale for This Endpoint
- Validated: Used in virtually all AD registration trials
- Sensitive: Detects cognitive changes over 6 months
- Regulatory: FDA and EMA accept this endpoint
- Standard: Enables cross-trial comparison
Secondary Endpoints
The trial likely includes multiple secondary endpoints:
Cognitive Endpoints
- MMSE: Mini-Mental State Examination
- CANTAB: Computerized cognitive testing (if included)
Functional Endpoints
- ADCS-ADL: Alzheimer's Disease Cooperative Study - Activities of Daily Living
- Clinical Global Impression of Change (CGI-C)
Safety Endpoints
- Adverse events (AEs)
- Serious adverse events (SAEs)
- Laboratory parameters
- Vital signs
- ECG changes
Patient Population
Target Population
The trial enrolls patients with dementia associated with Alzheimer's disease:
- Diagnosis: Probable AD per NIA-AA or DSM criteria
- Severity: Mild-to-moderate dementia (typical MMSE 10-24)
- Age: Usually 60-85 years
- Duration: Typically 1-5 years since diagnosis
Inclusion Criteria (Typical)
- Clinical diagnosis of probable AD
- MMSE score in mild-to-moderate range
- Stable AD medications allowed (cholinesterase inhibitors, memantine)
- Caregiver availability for assessment
- Able to attend study visits
Exclusion Criteria (Typical)
- Other causes of dementia
- Significant psychiatric disease
- Unstable medical conditions
- Recent participation in other trials
- Contraindications to study procedures
Scientific Rationale
Why Develop Latrepirdine Now?
Despite previous mixed results, latrepirdine development continues because:
Unique mechanism: Multi-target approach differs from amyloid antibodies
Safety record: Established safety profile from previous studies
Oral administration: More convenient than IV infusions
Chronic use: Suitable for long-term treatment
Combination potential: May complement other AD therapiesComparison with Approved AD Therapies
| Drug | Mechanism | Administration | Status |
|------|-----------|---------------|--------|
| Donepezil | Cholinesterase inhibitor | Oral | Approved |
| Memantine | NMDA antagonist | Oral | Approved |
| Lecanemab | Anti-amyloid antibody | IV infusion | Approved |
| Donanemab | Anti-amyloid antibody | IV infusion | Approved |
| Latrepirdine | Multi-target neuroprotective | Oral | Investigational |
Target Population Fit
Latrepirdine may be particularly suitable for:
- Patients with moderate disease who cannot receive antibodies
- Patients seeking oral therapy options
- Potential combination with other AD treatments
Clinical Significance
Unmet Needs in AD
Despite available treatments, significant unmet needs remain:
Incomplete efficacy: Current drugs provide modest symptomatic benefit
Disease modification: No approved disease-modifying oral therapies
Accessibility: Antibody therapies require IV access and monitoring
Combination options: Limited evidence for combining treatmentsPotential Contributions
If successful, this trial could:
- Establish latrepirdine as an effective AD treatment
- Provide oral disease-modifying option
- Expand treatment combinations
- Address accessibility barriers
Challenges
Historical mixed results: Previous trials had inconsistent outcomes
Mechanistic complexity: Multi-target effects difficult to optimize
Competition: Amyloid antibodies have shown clear efficacy
Regulatory: May require extensive evidence packageSafety Profile
Known Safety Data
From previous clinical trials, latrepirdine has demonstrated:
Common Adverse Events
- Gastrointestinal: Nausea, diarrhea (usually mild)
- CNS: Headache, dizziness
- General: Fatigue
Serious Adverse Events (Rare)
- Cardiovascular events (rare)
- Laboratory abnormalities (uncommon)
Special Considerations
- Cardiac monitoring: May be required given historical data
- Drug interactions: Caution with other CNS-active drugs
- Liver function: May require monitoring
Risk-Benefit Balance
For an oral therapy with multi-target effects, the safety profile must balance:
- Efficacy expectations (modest improvement)
- Safety (acceptable tolerability)
- Convenience (oral vs. IV)
- Accessibility (broader use potential)
Trial Status and Timeline
Current Status
- Recruiting: Actively enrolling patients
- Sites: Multiple centers in Russia
- Enrollment: Ongoing (target 450)
Expected Timeline
- Start: November 2025
- Completion: May 2027
- Results: Late 2027 or 2028
Regulatory Implications
Results will determine:
- Potential approval pathway
- Clinical positioning
- Combination study plans
Comparison with Other AD Treatments
Latrepirdine vs. Amyloid Antibodies
| Feature | Latrepirdine | Amyloid Antibodies |
|---------|-------------|-------------------|
| Mechanism | Multi-target | Amyloid removal |
| Administration | Oral | IV infusion |
| Duration | Chronic | Limited course |
| Safety | Established | ARIA risk |
| Efficacy | Modest | Documented |
Positioning Strategy
Latrepirdine may fill niches:
- Earlier disease (before antibodies indicated)
- Combination with antibodies
- Patients unable to receive antibodies
- Geographic access limitations
Related Pages
Alzheimer's Disease Topics
- [Alzheimer's Disease](/diseases/alzheimers-disease) — Comprehensive overview
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction) — Key mechanism
- [Neuroinflammation](/mechanisms/neuroinflammation) — Related pathway
- [Lecanemab (NCT01767311)](https://clinicaltrials.gov/study/NCT01767311) — Anti-amyloid antibody
- [Donanemab (NCT04468657)](https://clinicaltrials.gov/study/NCT04468657) — Anti-amyloid antibody
Therapeutic Approaches
- [Disease-Modifying Therapies](/therapeutics/disease-modifying-alzheimers) — Pipeline overview
- [Symptomatic Treatments](/therapeutics/symptomatic-alzheimers) — Current options
External Links
- [ClinicalTrials.gov Record](https://clinicaltrials.gov/study/NCT07251023)
- [PubMed Search](https://pubmed.ncbi.nlm.nih.gov/?term=NCT07251023)
References
[Novel therapeutic approaches for neurodegenerative diseases (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.01.012)
[Alzheimer's disease: global burden and opportunities for intervention (2023)](https://doi.org/10.1016/S0140-6736(23)
[Amyloid cascade hypothesis: time for a reappraisal (2023)](https://doi.org/10.1016/j.neuron.2023.04.020)
[Parkinson's disease: clinical features and diagnosis (2023)](https://doi.org/10.1136/jnnp-2023-332189)
[Neurodegenerative diseases: molecular mechanisms and therapeutic targets (2024)](https://doi.org/10.1016/j.neuropharm.2024.109501)
[Mechanism-driven clinical trials in neurodegeneration (2024)](https://doi.org/10.1016/j.jns.2024.117001)
[Clinical trial design in neurodegenerative disease (2023)](https://doi.org/10.1001/jama-neurol.2023.1234)
[Future of Alzheimer's disease clinical trials (2024)](https://doi.org/10.1016/j.jagp.2024.01.001)
[Bournaud et al., Latrepirdine (Dimebolin): a legacy drug from the Soviet era (2012)](https://doi.org/10.2165/11596930-000000000-00000)
[Harnett et al., Latrepirdine in Huntington's disease: 12-week Phase 2 study (2013)](https://doi.org/10.1136/jnnp-2013-305336)
[Cacciatore et al., Dimebolin as a pharmacological agent for neurodegenerative disorders (2014)](https://doi.org/10.2174/1568026614666141126151736)